Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/246958
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Protective Role of Cortistatin in Pulmonary Inflammation and Fibrosis |
Otros títulos: | Cortistatin protects from experimental ALI/ARDS | Autor: | Barriga, Margarita; Benitez, Raquel; Ferraz-de-Paula, Viviane; Garcia-Frutos, Marina; Caro, Marta; Robledo, Gema; O’Valle, Francisco; Campos-Salinas, Jenny; Delgado, Mario | Palabras clave: | Acute lung injury Pulmonary inflammation Fibroblasts Macrophages Neuropeptide |
Fecha de publicación: | 8-jul-2021 | Editor: | John Wiley & Sons | Citación: | British Journal of Pharmacology (2021) | Resumen: | Background and Purpose Acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and pulmonary fibrosis remain major causes of morbidity, mortality and healthcare burden in the critically ill patient. There is an urgent medical need for identifying factors of susceptibility and prognosis and for designing new therapeutic tools for treating these disorders. Here, we evaluate the capacity of the immunomodulatory neuropeptide cortistatin to regulate pulmonary inflammation and fibrosis in vivo. Experimental Approach ALI/ARDS and pulmonary fibrosis were induced experimentally in wild-type and cortistatin-deficient mice by pulmonary infusion of the bacterial endotoxin LPS or the chemotherapeutic drug bleomycin, and the histopathological signs, pulmonary leukocyte infiltration and cytokines and fibrotic markers were evaluated. Key Results Partially-deficient mice in cortistatin showed exacerbated pulmonary damage, pulmonary inflammation, alveolar oedema and fibrosis, and subsequent increased respiratory failure and mortality when challenged to LPS or bleomycin, even at low doses. Treatment with cortistatin reversed these aggravated phenotypes and protected from progression to severe ARDS and fibrosis after high-exposition to both injury agents. Moreover, cortistatin-deficient pulmonary macrophages and fibroblasts showed exaggerated ex vivo inflammatory and fibrotic responses, and treatment with cortistatin impaired their activation. Finally, the protective effects of cortistatin in ALI and pulmonary fibrosis were partially inhibited by specific antagonists for somatostatin- and ghrelin-receptors. Conclusion and Implications We identify to cortistatin as an endogenous break of pulmonary inflammation and fibrosis. Deficiency in cortistatin could be a marker of poor-prognosis in inflammatory/fibrotic pulmonary disorders. Cortistatin-based therapies emerge as attractive candidates to treat severe ALI/ARDS, including SARS-Cov-2-associated ARDS. | Versión del editor: | https://doi.org/10.1111/bph.15615 | URI: | http://hdl.handle.net/10261/246958 | DOI: | 10.1111/bph.15615 | ISSN: | 0007-1188 | E-ISSN: | 1476-5381 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (IPBLN) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
13
checked on 22-abr-2024
WEB OF SCIENCETM
Citations
11
checked on 22-feb-2024
Page view(s)
106
checked on 24-abr-2024
Download(s)
31
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.